ARTHEx Biotech upsized its Series B financing round to $87M to advance ATX-01 in myotonic dystrophy type 1.
ARTHEx Biotech is a clinical-stage biotechnology company focused on developing RNA-based therapeutics targeting neuromuscular disorders, particularly Myotonic Dystrophy Type 1
ARTHEx Biotech is a clinical-stage biotechnology company focused on developing RNA-based therapeutics targeting neuromuscular disorders, particularly Myotonic Dystrophy Type 1.